

Diaceutics PLC

PDMR Shareholding/Share Incentive Plan

New York, Belfast and London, 30 January 2025 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, has been notified that on 28 January 2025, Global Shares Trustees (UK) Limited (the "UK Trust") and Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust, have purchased ordinary shares of £0.002 in the capital of the Company ("Shares") on behalf of Susanne Munksted, Jordan Clark, Nick Roberts and Jillian Beggs (PDMRs), in respect of their purchase of Shares pursuant to the Company's UK and Global Share Incentive Plan ("the SIP Schemes") for employees. These purchases will be made each month until further notice.

In accordance with the SIP Schemes, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 1:1.

Enquiries:

Diaceutics PLC
Ryan Keeling, Chief Executive Officer
Nick Roberts, Chief Financial Officer

Canaccord Genuity Limited (Nomad & Broker)
Simon Bridges, Andrew Potts, Harry Rees

Tel: +44 (0)28 9040 6500
investorrelations@diaceutics.com

Tel: +44 (0)20 7253 8000

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.

| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | | | |
|---|---|--|--|
| 1 | Details of the person discharging managerial responsibilities/person closely associated | | |
| a. | Name | Susanne Munksted | |
| 2 | Reason for notification | | |
| a. | Position/Status | Chief Precision Medicine Officer | |
| b. | Initial notification/ Amendment | Initial | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | |
| a. | Name | Diaceutics PLC | |
| b. | LEI | 213800VEWQBB39ZB8J81 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | |
| a. | Description of the financial instrument, type of instrument Identification Code | Ordinary shares of £0.002 each ISIN: GB00BJQTGV64 | |
| b. | Nature of the transaction | Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Global Share Incentive Plan ("SIP") | |
| c. | Price(s) and volume(s) | Share purchase | |

| | | | | | | | | | |
|----|--------------------------|--|--------------------------|-----------|--|--|--|--|--|
| c. | Price(s) and volume(s) | | Share purchase: | | | | | | |
| | | | Price(s) | Volume(s) | | | | | |
| | | | 144 p | 101 | | | | | |
| | | | Conditional share award: | | | | | | |
| | | | Price(s) | Volume(s) | | | | | |
| | | | Nil | 101 | | | | | |
| | | | | | | | | | |
| e. | Date of the transaction | Share purchase and Conditional share award: 28 January 2025 | | | | | | | |
| f. | Place of the transaction | Share Purchase: AIM Market of the London Stock Exchange Conditional share award: Off-Market | | | | | | | |

| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | | | | |
|--|--|---|----------|-----------|
| 1 Details of the person discharging managerial responsibilities/person closely associated | | | | |
| a. | Name | Jordan Clark | | |
| 2 Reason for notification | | | | |
| a. | Position/Status | Chief Data Officer | | |
| b. | Initial notification/ Amendment | Initial | | |
| 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | |
| a. | Name | Diaceutics PLC | | |
| b. | LEI | 213800VEWQBB39ZB8J81 | | |
| 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | | | |
| a. | Description of the financial instrument, type of instrument Identification Code | Ordinary shares of £0.002 each ISIN: GB00BJQTGV64 | | |
| b. | Nature of the transaction | Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP") | | |
| c. | Price(s) and volume(s) | Share purchase: | | |
| | | <table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>144 p</td> <td>104</td> </tr> </table> | Price(s) | Volume(s) |
| Price(s) | Volume(s) | | | |
| 144 p | 104 | | | |
| Matched share award: | | | | |
| <table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>Nil</td> <td>104</td> </tr> </table> | Price(s) | Volume(s) | Nil | 104 |
| Price(s) | Volume(s) | | | |
| Nil | 104 | | | |
| | | | | |
| | | | | |
| | | | | |
| e. | Date of the transaction | Share purchase and Matched Share award: 28 January 2025 | | |
| f. | Place of the transaction | Share Purchase: AIM Market of the London Stock Exchange | | |

| | | |
|--|--|---------------------------------|
| | | Matched Share Award: Off-Market |
|--|--|---------------------------------|

| | | | | | | | | | | | | |
|--|--|---|----------|-----------|-------|-----|----------------------|--|----------|-----------|-----|-----|
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | | | | | | | | | | | | |
| 1 Details of the person discharging managerial responsibilities/person closely associated | | | | | | | | | | | | |
| a. | Name | Nick Roberts | | | | | | | | | | |
| 2 Reason for notification | | | | | | | | | | | | |
| a. | Position/Status | Chief Finance Officer | | | | | | | | | | |
| b. | Initial notification/ Amendment | Initial | | | | | | | | | | |
| 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | | | | | | | | | |
| a. | Name | Diaceutics PLC | | | | | | | | | | |
| b. | LEI | 213800VEWQBB39ZB8J81 | | | | | | | | | | |
| 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | | | | | | | | | | | |
| a. | Description of the financial instrument, type of instrument Identification Code | Ordinary shares of £0.002 each ISIN: GB00BJQTGV64 | | | | | | | | | | |
| b. | Nature of the transaction | Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP") | | | | | | | | | | |
| c. | Price(s) and volume(s) | Share purchase: <table border="1" style="margin-left: 20px;"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>144 p</td> <td>104</td> </tr> <tr> <td colspan="2">Matched share award:</td> </tr> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>Nil</td> <td>104</td> </tr> </table> | Price(s) | Volume(s) | 144 p | 104 | Matched share award: | | Price(s) | Volume(s) | Nil | 104 |
| Price(s) | Volume(s) | | | | | | | | | | | |
| 144 p | 104 | | | | | | | | | | | |
| Matched share award: | | | | | | | | | | | | |
| Price(s) | Volume(s) | | | | | | | | | | | |
| Nil | 104 | | | | | | | | | | | |
| e. | Date of the transaction | Share purchase and Matched Share award: 28 January 2025 | | | | | | | | | | |
| f. | Place of the transaction | Share Purchase: AIM Market of the London Stock Exchange Matched Share Award: Off-Market | | | | | | | | | | |

| | | |
|--|------|---------------|
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | | |
| 1 Details of the person discharging managerial responsibilities/person closely associated | | |
| a. | Name | Jillian Beggs |
| 2 Reason for notification | | |

| | | | | | | | | | | | | | |
|----------------------|---|--|--|----------|-----------|-------|-----|----------------------|--|----------|-----------|-----|-----|
| a. | Position/Status | Chief Commercial Officer | | | | | | | | | | | |
| b. | Initial notification/ Amendment | Initial | | | | | | | | | | | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | | | | | | | | | |
| a. | Name | Diaceutics PLC | | | | | | | | | | | |
| b. | LEI | 213800VEWQBB39ZB8J81 | | | | | | | | | | | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | | | | | | | | | | | |
| a. | Description of the financial instrument, type of instrument Identification Code | Ordinary shares of £0.002 each ISIN: GB00BJQTGV64 | | | | | | | | | | | |
| b. | Nature of the transaction | Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP") | | | | | | | | | | | |
| c. | Price(s) and volume(s) | <div>Share purchase:</div> <table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>144 p</td><td>104</td></tr><tr><td colspan="2">Matched share award:</td></tr><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>Nil</td><td>104</td></tr></table> | | Price(s) | Volume(s) | 144 p | 104 | Matched share award: | | Price(s) | Volume(s) | Nil | 104 |
| Price(s) | Volume(s) | | | | | | | | | | | | |
| 144 p | 104 | | | | | | | | | | | | |
| Matched share award: | | | | | | | | | | | | | |
| Price(s) | Volume(s) | | | | | | | | | | | | |
| Nil | 104 | | | | | | | | | | | | |
| e. | Date of the transaction | Share purchase and Matched Share award: 28 January 2025 | | | | | | | | | | | |
| f. | Place of the transaction | Share Purchase: AIM Market of the London Stock Exchange Matched Share Award: Off-Market | | | | | | | | | | | |

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHSDLFFSEISEEF